ContraFect Corp. (CFRX) PT Raised to $17.50 at Chardan Capital Markets

Go back to ContraFect Corp. (CFRX) PT Raised to $17.50 at Chardan Capital Markets

ContraFect (CFRX) Prices 10M Share Common Offering at $5/Sh

March 18, 2021 6:03 AM EDT

ContraFect Corporation (NASDAQ: CFRX), a clinical-stage biotechnology company focused on discovering and developing direct lytic agents for the treatment of life-threatening infectious diseases, today announced the pricing of its underwritten public offering of 10,000,000 shares of its common stock at a public offering price of $5.00 per share. ContraFect has also granted the underwriters a 30-day option to purchase up to an additional 1,500,000 shares of its common... More